Amylyx Pharmaceuticals Inc (AMLX) — Capital Reinvestment Ratio

Latest as of December 2023: 0.03x

Amylyx Pharmaceuticals Inc (AMLX) has a Capital Reinvestment Ratio of 0.03x as of December 2023, meaning it reinvests 0% of its operating cash flow ($13.55 Million) in capital expenditures ($356.00K). Check how tangible is Amylyx Pharmaceuticals Inc's equity to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.03x
Capex / Operating Cash Flow

Operating Cash Flow

$13.55 Million
USD

Capital Expenditures

$356.00K
USD

Data as of

Dec 2023
Most recent filing

Amylyx Pharmaceuticals Inc Capital Reinvestment Ratio (2023–2023)

This chart tracks Amylyx Pharmaceuticals Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Amylyx Pharmaceuticals Inc.

Annual Capital Reinvestment Ratio for Amylyx Pharmaceuticals Inc (2023–2023)

Year-by-year Capital Reinvestment Ratio for Amylyx Pharmaceuticals Inc from 2023 to 2023. See Amylyx Pharmaceuticals Inc (AMLX) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2023 0.10x $11.92 Million $1.24 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow